• 1. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Recent Advances in the Study of 6-Chloro-2-(methylamino)-3-nitrobenzonitrile (CAS: 333458-39-2)

6-Chloro-2-(methylamino)-3-nitrobenzonitrile (CAS: 333458-39-2) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, biological activity, and potential therapeutic uses, particularly in the context of kinase inhibition and anticancer activity. This research brief aims to summarize the latest findings related to this compound, providing a comprehensive overview of its current status in scientific research.

The compound's structural features, including the chloro, nitro, and nitrile functional groups, make it a promising scaffold for the development of novel bioactive molecules. Recent synthetic approaches have optimized the yield and purity of 6-Chloro-2-(methylamino)-3-nitrobenzonitrile, enabling more extensive biological evaluations. Advanced spectroscopic techniques, such as NMR and mass spectrometry, have been employed to confirm its structure and purity, ensuring reliable data for subsequent studies.

In vitro studies have demonstrated that 6-Chloro-2-(methylamino)-3-nitrobenzonitrile exhibits potent inhibitory activity against specific kinases, which are critical targets in cancer therapy. Molecular docking simulations have revealed its binding affinity to the ATP-binding sites of these kinases, suggesting a competitive inhibition mechanism. These findings are supported by enzymatic assays showing IC50 values in the low micromolar range, highlighting its potential as a lead compound for further optimization.

Further investigations into the compound's pharmacokinetic properties have provided insights into its absorption, distribution, metabolism, and excretion (ADME) profiles. While the compound shows moderate solubility and permeability, its metabolic stability has been a point of concern, prompting researchers to explore structural modifications to enhance its drug-like properties. Recent efforts have focused on derivatization strategies to improve bioavailability and reduce potential toxicity.

In vivo studies using animal models have begun to evaluate the efficacy and safety of 6-Chloro-2-(methylamino)-3-nitrobenzonitrile. Preliminary results indicate promising antitumor activity in xenograft models, with observed reductions in tumor volume and minimal adverse effects. These findings underscore the compound's potential as a candidate for further preclinical development, although additional studies are needed to fully characterize its therapeutic window and long-term safety.

Beyond its anticancer potential, recent research has explored other therapeutic applications of 6-Chloro-2-(methylamino)-3-nitrobenzonitrile. For instance, its interaction with other biological targets, such as inflammatory mediators and microbial enzymes, has been investigated. These studies suggest a broader pharmacological profile, opening new avenues for its use in treating diverse diseases, including infectious and inflammatory conditions.

In conclusion, 6-Chloro-2-(methylamino)-3-nitrobenzonitrile (CAS: 333458-39-2) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its kinase inhibitory activity, coupled with its potential for structural optimization, positions it as a valuable lead for drug development. Continued research efforts are expected to further elucidate its mechanisms of action, refine its pharmacokinetic properties, and expand its therapeutic applications. This brief highlights the current state of knowledge and underscores the importance of ongoing investigations to fully realize its potential in medicine.

• 333459-71-5(Benzonitrile, 2-amino-6-chloro-3-nitro-)
• 784194-67-8(2-(4-Chlorophenyl)amino-5-nitrobenzonitrile)
• 6575-07-1(2-Chloro-6-nitrobenzonitrile)
• 2112-15-4(2-Chloro-4-methyl-6-nitrobenzonitrile)
• 172455-36-6(5-Chloro-4-cyano-2-nitroaniline)
• 40318-83-0
• 660862-08-8(Benzonitrile, 2-[(4-chloro-2-nitrophenyl)amino]-5-(1-methylethyl)-)
• 660862-06-6(Benzonitrile, 2-[(4-chloro-2-nitrophenyl)amino]-5-methyl-)
• 40318-84-1(Benzenamine, 4-chloro-N,N,3-trimethyl-2,6-dinitro-)
• 945299-67-2(2-(3-Chloro-2-methylphenyl)amino-5-nitrobenzonitrile)